115563
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
纳米赋能治疗：子痫前期治疗的新策略
Authors Huang Y, Zhang X, Xue L, He C
Received 31 October 2025
Accepted for publication 24 December 2025
Published 15 January 2026 Volume 2026:21 578148
DOI https://doi.org/10.2147/IJN.S578148
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. RDK Misra
Yimin Huang,1 Xiaojuan Zhang,2 Lili Xue,3 Chuanchuan He1
1Department of Central Laboratory, Jiaxing Maternity and Child Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, People’s Republic of China; 2Department of Pharmaceutics, College of Medicine, Jiaxing University, Jiaxing, People’s Republic of China; 3Department of Obstetrics, Jiaxing Maternity and Child Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, People’s Republic of China
Correspondence: Lili Xue, Jiaxing Maternity and Child Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, People’s Republic of China, Email beibeixuelili@163.com Chuanchuan He, Jiaxing Maternity and Child Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, People’s Republic of China, Email hechuanchuan@zjxu.edu.cn
Abstract: Preeclampsia (PE), a pregnancy-specific disorder characterized by hypertension and placental dysfunction, remains a leading cause of maternal and fetal morbidities worldwide. Recent advances in nanomedicine offer promising therapeutic strategies by targeting placental pathologies. Studies have demonstrated that in PE mouse models, the regulation of key disease-related genes (such as sFlt1 and VEGF) using siRNA- or mRNA-loaded carriers (eg, lipid nanoparticles, exosomes, or elastin-like polypeptides) can effectively alleviate PE symptoms. This review summarizes the progress in nanoparticle-based therapies for PE, discusses challenges such as scalability and clinical translation, and highlights the potential of nanomedicine to revolutionize PE management.
Keywords: preeclampsia, nanocarrier, placenta, sFlt1
1Department of Central Laboratory, Jiaxing Maternity and Child Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, People’s Republic of China; 2Department of Pharmaceutics, College of Medicine, Jiaxing University, Jiaxing, People’s Republic of China; 3Department of Obstetrics, Jiaxing Maternity and Child Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, People’s Republic of China
Correspondence: Lili Xue, Jiaxing Maternity and Child Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, People’s Republic of China, Email beibeixuelili@163.com Chuanchuan He, Jiaxing Maternity and Child Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, People’s Republic of China, Email hechuanchuan@zjxu.edu.cn
Abstract: Preeclampsia (PE), a pregnancy-specific disorder characterized by hypertension and placental dysfunction, remains a leading cause of maternal and fetal morbidities worldwide. Recent advances in nanomedicine offer promising therapeutic strategies by targeting placental pathologies. Studies have demonstrated that in PE mouse models, the regulation of key disease-related genes (such as sFlt1 and VEGF) using siRNA- or mRNA-loaded carriers (eg, lipid nanoparticles, exosomes, or elastin-like polypeptides) can effectively alleviate PE symptoms. This review summarizes the progress in nanoparticle-based therapies for PE, discusses challenges such as scalability and clinical translation, and highlights the potential of nanomedicine to revolutionize PE management.
Keywords: preeclampsia, nanocarrier, placenta, sFlt1